Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Minute Insight: Illumina Seeks Stability, Names Thaysen As New CEO

Executive Summary

The genome-sequencing giant has named Jacob Thaysen, who brings extensive experience from Agilent, as its new leader.

You may also be interested in...

Minute Insight: Guardant And Illumina Resolve Litigation, Agree To Partnership

Illumina sued Guardant last year, claiming Guardant’s founders stole trade secrets related to blood biopsy diagnostics. The companies have agreed to drop that dispute and share specimen samples for cancer research.

Illumina Creeps Closer To Half-Billion-Dollar Fine

The sequencing giant could be pilloried in Europe and may have to pay a record-breaking fine.

CEO Resignation Raises Doubts About Illumina’s Commitment To Grail

Francis deSouza resigned as CEO and chairman of Illumina just a few weeks after winning the support of shareholders. General counsel Charles Dadswell will take over as interim CEO.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts